<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00632489</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI REFMAL 119</org_study_id>
    <nct_id>NCT00632489</nct_id>
  </id_info>
  <brief_title>LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients</brief_title>
  <official_title>A Phase I Study of LBH589 in Combination With Capecitabine ± Lapatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single center Phase I dose escalation trial will evaluate the safety, tolerability and&#xD;
      efficacy of LBH589 when combined with capecitabine and lapatinib in three parts. Part 1 will&#xD;
      determine the maximum tolerated doses (MTD) of LBH589 when combined with capecitabine. Parts&#xD;
      2 and 3 will be limited to locally recurrent or metastatic breast cancer patients, ICH 3+&#xD;
      overexpression or FISH amplification documented locally. Part 2 will evaluate the safety of&#xD;
      the MTD of LBH589 determined in Part 1 when paired with lapatinib 1000 mg by mouth (PO)&#xD;
      daily. Parts 2 and 3 will be limited to locally recurrent or metastatic breast cancer&#xD;
      patients, ICH 3+ overexpression or FISH amplification documented locally. Part 3 will&#xD;
      evaluate the tolerability and effectiveness of the triplet combination, LBH589, capecitabine&#xD;
      and lapatinib in breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LBH589 will be evaluated when administered twice weekly at the following possible dose&#xD;
      levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will&#xD;
      range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles&#xD;
      will be 21 days in length. Once determined safe, 10 additional patients will be treated at&#xD;
      the determined MTD to further assess safety.&#xD;
&#xD;
      The second portion of this study will assess QTc prolongation with the LBH589 and lapatinib&#xD;
      combination. A subset of 6 patients will be treated with the LBH589 one dose below the MTD&#xD;
      determined during Part I. If tolerated, 6 additional patients will receive LBH589 at the MTD&#xD;
      established in Part I with lapatinib (capecitabine will not be administered in this subset of&#xD;
      patients).&#xD;
&#xD;
      If there are no clinically significant findings in the LBH589 and lapatinib subset, the study&#xD;
      will advance to a third portion which combines the three drugs LBH589, capecitabine, and&#xD;
      lapatinib.&#xD;
&#xD;
      The triple combination will initially administer lapatinib 1000 mg orally daily with LBH589&#xD;
      and capecitabine at one dose level below the established MTD. If tolerated, LBH589 and&#xD;
      capecitabine doses will be escalated to the MTD.&#xD;
&#xD;
      Toxicity assessments will be ongoing and disease assessments will be repeated every 2&#xD;
      treatment cycles. If all dose level combinations are explored, a total of 45-55 patients will&#xD;
      be required to accommodate for the additional patients enrolled in the QTc subset and to&#xD;
      establish the recommended phase II dose of the combination regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine the Maximum Tolerated Doses (MTD) and Dose-limiting Toxicities (DLT) of LBH589 in Combination With Capecitabine When Administered to Patients With Refractory and Advanced Tumor Types That Are Sensitive to 5-fluorouracil</measure>
    <time_frame>18 months</time_frame>
    <description>MTD for Capecitabine, BID</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Determine the Maximum Tolerated Doses (MTD) and Dose-limiting Toxicities (DLT) of LBH589 in Combination With Capecitabine When Administered to Patients With Refractory and Advanced Tumor Types That Are Sensitive to 5-fluorouracil</measure>
    <time_frame>18 months</time_frame>
    <description>MTD for Panobinostat, twice weekly</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Antitumor Activity of LBH589 in Combination With Capecitabine in Patients With Refractory and Advanced Tumors</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Tolerability and Preliminary Efficacy of Established Doses of LBH589 and Capecitabine With Lapatinib in a Limited Number of Patients With HER2+ Breast Cancer</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LBH589 with Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTD, LBH589 with Capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBH589 and Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LBH589 and Lapatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBH589, Capecitabine and Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBH589</intervention_name>
    <description>LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.</description>
    <arm_group_label>LBH589 and Lapatinib</arm_group_label>
    <arm_group_label>LBH589 with Capecitabine</arm_group_label>
    <arm_group_label>LBH589, Capecitabine and Lapatinib</arm_group_label>
    <other_name>Panobinostat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine will be administered orally twice daily for 14 days out of every 21 days.</description>
    <arm_group_label>LBH589 with Capecitabine</arm_group_label>
    <arm_group_label>LBH589, Capecitabine and Lapatinib</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Lapatinib, 1000 mg PO daily will be added to this combination.</description>
    <arm_group_label>LBH589 and Lapatinib</arm_group_label>
    <arm_group_label>LBH589, Capecitabine and Lapatinib</arm_group_label>
    <other_name>Tykerb</other_name>
    <other_name>Tyverb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically documented metastatic or locally unresectable, incurable malignancy for&#xD;
             which capecitabine is clinically appropriate.&#xD;
&#xD;
          2. Male or female patients aged ≥ 18 years old.&#xD;
&#xD;
          3. Maximum of 3 prior regimens in a metastatic setting allowed and may include other&#xD;
             targeted agents, immunotherapy and chemotherapy.&#xD;
&#xD;
          4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.&#xD;
&#xD;
          6. Baseline MUGA or ECHO must demonstrate LVEF &gt; than the lower limits of the&#xD;
             institutional normal.&#xD;
&#xD;
          7. Laboratory values as follows:&#xD;
&#xD;
               -  ANC &gt; 1500/μL&#xD;
&#xD;
               -  Hgb &gt; 9 g/dL&#xD;
&#xD;
               -  Platelets &gt; 100,000/uL&#xD;
&#xD;
               -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
               -  AST/SGOT &lt; 2.5 x ULN or &lt; 5.0 x ULN and ALT/SGPT in patients with liver&#xD;
                  metastases&#xD;
&#xD;
               -  Creatinine &lt; 1.5 mg/dL or calculated creatinine clearance &gt; 50 ml/min&#xD;
&#xD;
               -  Albumin &gt; 3 g/dL&#xD;
&#xD;
               -  Potassium &gt; lower limit of normal (LLN)&#xD;
&#xD;
               -  Phosphorous &gt; LLN&#xD;
&#xD;
               -  Calcium &gt; LLN&#xD;
&#xD;
               -  Magnesium &gt; LLN&#xD;
&#xD;
          8. Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             performed within 7 days prior to start of treatment and must commit to begin two&#xD;
             acceptable methods of birth control, one highly effective method of birth control and&#xD;
             one additional effective method at the same time before starting treatment.&#xD;
&#xD;
          9. Life expectancy &gt; 12 weeks.&#xD;
&#xD;
         10. Accessible for treatment and follow-up.&#xD;
&#xD;
         11. All patients must be able to understand the nature of the study and give written&#xD;
             informed consent prior to study entry.&#xD;
&#xD;
        Additional Breast Cancer Patient Subset (Part 2 and Part 3) Inclusion Criteria:&#xD;
&#xD;
          1. Incurable carcinoma of the breast, with measurable locally recurrent or metastatic&#xD;
             disease.&#xD;
&#xD;
          2. ICH 3+ overexpression or FISH amplification documented by a local laboratory in&#xD;
             primary or metastatic tumor tissue.&#xD;
&#xD;
          3. Prior treatment with an anthracycline, taxane, and trastuzumab or not a candidate for&#xD;
             such treatment. Patient may have received these drugs in combination or in sequence&#xD;
             for the treatment of locally advanced or metastatic disease and/or adjuvant therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with an HDAC inhibitor or current treatment with valproic acid.&#xD;
&#xD;
          2. Previous treatment with capecitabine.&#xD;
&#xD;
          3. Impaired cardiac function including any of the following:&#xD;
&#xD;
               -  Screening ECG with a QTc &gt; 450 msec.&#xD;
&#xD;
               -  Congenital long QT syndrome.&#xD;
&#xD;
               -  History of sustained ventricular tachycardia.&#xD;
&#xD;
               -  Any history of ventricular fibrillation or torsades de pointes.&#xD;
&#xD;
               -  Bradycardia defined as heart rate &lt; 50 beats per minute. Patients with a&#xD;
                  pacemaker and heart rate &gt; 50 beats per minute are eligible.&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months of study entry.&#xD;
&#xD;
               -  Congestive heart failure (NY Heart Association class III or IV).&#xD;
&#xD;
               -  Right bundle branch block and left anterior hemiblock (bifascicular block).&#xD;
&#xD;
               -  Atrial fibrillation or flutter.&#xD;
&#xD;
               -  Ongoing therapy with antiarrhythmics or other medications associated with QTc&#xD;
                  prolongation.&#xD;
&#xD;
          4. Uncorrected hypokalemia or hypomagnesaemia.&#xD;
&#xD;
          5. Uncontrolled hypertension (systolic blood pressure [BP] 180 or diastolic BP &gt; 100 mm&#xD;
             Hg) or uncontrolled cardiac arrhythmias.&#xD;
&#xD;
          6. Active CNS disease, including meningeal metastases.&#xD;
&#xD;
          7. Known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          8. Unresolved diarrhea &gt; CTCAE grade 1.&#xD;
&#xD;
          9. Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors.&#xD;
&#xD;
         10. Patients with a history of allergic reactions attributed to compounds of similar&#xD;
             chemical or biologic composition to lapatinib.&#xD;
&#xD;
         11. Patients with known hypersensitivity to 5-fluorouracil chemotherapy, investigational&#xD;
             drug therapy, major surgery &lt; 4 weeks prior to starting study drug or patients that&#xD;
             have not recovered from side effects of previous therapy.&#xD;
&#xD;
         12. Patient is &lt; 5 years free of another primary malignancy except if the other primary&#xD;
             malignancy is not currently clinically significant or requiring active intervention,&#xD;
             or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in&#xD;
             situ. Existence of any other malignant disease is not allowed.&#xD;
&#xD;
         13. Concomitant use of any anti-cancer therapy or radiation therapy.&#xD;
&#xD;
         14. Pregnant or breast feeding or female of reproductive potential not using two effective&#xD;
             methods of birth control.&#xD;
&#xD;
         15. Male patients whose sexual partners are women of childbearing potential not using&#xD;
             effective birth control.&#xD;
&#xD;
         16. Patients with gastrointestinal (GI) tract disease, causing the inability to take oral&#xD;
             medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation,&#xD;
             prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease&#xD;
             (e.g., Crohn's disease, ulcerative colitis).&#xD;
&#xD;
         17. Other concurrent severe, uncontrolled infection or intercurrent illness, including but&#xD;
             not limited to ongoing or active infection, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements.&#xD;
&#xD;
         18. Patients taking any medications listed in &quot;Prohibited Medications&quot; for both&#xD;
             capecitabine and lapatinib .&#xD;
&#xD;
         19. Patients with uncontrolled coagulopathy (PT and/or PTT &gt; 1.2 x ULN; patient must also&#xD;
             be on stable dose of anticoagulant for a defined medical indication).&#xD;
&#xD;
         20. Abnormal thyroid function (TSH or free T4) detected at screening. Patients with known&#xD;
             hypothyroidism who are stable on thyroid replacement are eligible.&#xD;
&#xD;
        Additional Breast Cancer Patient Subset (Part 2 and Part 3) Exclusion Criteria:&#xD;
&#xD;
        1. Prior treatment with lapatinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard A Burris, III, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2008</study_first_posted>
  <results_first_submitted>May 18, 2015</results_first_submitted>
  <results_first_submitted_qc>June 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2015</results_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory Malignancy</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>LBH589</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Lapatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LBH589 With Capecitabine</title>
          <description>MTD, LBH589 with Capecitabine&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.</description>
        </group>
        <group group_id="P2">
          <title>LBH589 and Lapatinib</title>
          <description>LBH589 and Lapatinib&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
        </group>
        <group group_id="P3">
          <title>LBH589, Capecitabine and Lapatinib</title>
          <description>LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Pts remained on study until disease progression, intolerable toxicity or other reason to discontinue</participants>
                <participants group_id="P2" count="0">Pts remained on study until disease progression, intolerable toxicity or other reason to discontinue</participants>
                <participants group_id="P3" count="0">Pts remained on study until disease progression, intolerable toxicity or other reason to discontinue</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LBH589 With Capecitabine</title>
          <description>MTD, LBH589 with Capecitabine&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.</description>
        </group>
        <group group_id="B2">
          <title>LBH589 and Lapatinib</title>
          <description>LBH589 and Lapatinib&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
        </group>
        <group group_id="B3">
          <title>LBH589, Capecitabine and Lapatinib</title>
          <description>LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="45" upper_limit="69"/>
                    <measurement group_id="B2" value="66" lower_limit="64" upper_limit="68"/>
                    <measurement group_id="B4" value="56" lower_limit="45" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine the Maximum Tolerated Doses (MTD) and Dose-limiting Toxicities (DLT) of LBH589 in Combination With Capecitabine When Administered to Patients With Refractory and Advanced Tumor Types That Are Sensitive to 5-fluorouracil</title>
        <description>MTD for Capecitabine, BID</description>
        <time_frame>18 months</time_frame>
        <population>MTD Determination only for part I patients (per protocol)</population>
        <group_list>
          <group group_id="O1">
            <title>LBH589 With Capecitabine</title>
            <description>MTD, LBH589 with Capecitabine&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.</description>
          </group>
          <group group_id="O2">
            <title>LBH589 and Lapatinib</title>
            <description>LBH589 and Lapatinib&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
          </group>
          <group group_id="O3">
            <title>LBH589, Capecitabine and Lapatinib</title>
            <description>LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Maximum Tolerated Doses (MTD) and Dose-limiting Toxicities (DLT) of LBH589 in Combination With Capecitabine When Administered to Patients With Refractory and Advanced Tumor Types That Are Sensitive to 5-fluorouracil</title>
          <description>MTD for Capecitabine, BID</description>
          <population>MTD Determination only for part I patients (per protocol)</population>
          <units>mg/m2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Antitumor Activity of LBH589 in Combination With Capecitabine in Patients With Refractory and Advanced Tumors</title>
        <time_frame>18 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Tolerability and Preliminary Efficacy of Established Doses of LBH589 and Capecitabine With Lapatinib in a Limited Number of Patients With HER2+ Breast Cancer</title>
        <time_frame>18 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Determine the Maximum Tolerated Doses (MTD) and Dose-limiting Toxicities (DLT) of LBH589 in Combination With Capecitabine When Administered to Patients With Refractory and Advanced Tumor Types That Are Sensitive to 5-fluorouracil</title>
        <description>MTD for Panobinostat, twice weekly</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LBH589 With Capecitabine</title>
            <description>MTD, LBH589 with Capecitabine&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.</description>
          </group>
          <group group_id="O2">
            <title>LBH589 and Lapatinib</title>
            <description>LBH589 and Lapatinib&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
          </group>
          <group group_id="O3">
            <title>LBH589, Capecitabine and Lapatinib</title>
            <description>LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Maximum Tolerated Doses (MTD) and Dose-limiting Toxicities (DLT) of LBH589 in Combination With Capecitabine When Administered to Patients With Refractory and Advanced Tumor Types That Are Sensitive to 5-fluorouracil</title>
          <description>MTD for Panobinostat, twice weekly</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LBH589 With Capecitabine</title>
          <description>MTD, LBH589 with Capecitabine&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.</description>
        </group>
        <group group_id="E2">
          <title>LBH589 and Lapatinib</title>
          <description>LBH589 and Lapatinib&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
        </group>
        <group group_id="E3">
          <title>LBH589, Capecitabine and Lapatinib</title>
          <description>LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)&#xD;
LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.&#xD;
Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.&#xD;
Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions - Other, disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders - Other, change in mental status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review/embargo results communications prior to public release for a period that is &gt;60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John D Hainsworth, MD</name_or_title>
      <organization>Sarah Cannon Research Institute</organization>
      <phone>1-877-691-7274</phone>
      <email>asksarah@scresearch.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

